---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-25-005405"
form_type: "8-K"
ticker: "INKT"
cik: "0001840229"
company_name: "MiNK Therapeutics, Inc."
filed_at: "2025-08-14T23:59:59+00:00"
generated_at: "2026-05-17T13:24:36.161044+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# MiNK Therapeutics Q2 2025 net loss $4.2M; extends runway with $13M raise; GvHD grants awarded

## Summary
- Cash at Q2 end $1.6M; raised $13M post-quarter; runway extended beyond mid-2026.
- Net loss Q2 2025 $4.2M ($1.06/shr) vs $2.7M ($0.73/shr) in Q2 2024.
- Durable complete remission in metastatic testicular cancer published; patient disease-free >2 years.
- DOD STTR grant and new clinical grant awarded for iNKT cell therapy in GvHD; trial target 2H2025.
- Phase 2 gastric cancer trial of agenT-797 expects additional readouts in 2025.

## SEC filing metadata
- accession: 0001171843-25-005405
- form_type: 8-K
- ticker: INKT
- cik: 0001840229
- company_name: MiNK Therapeutics, Inc.
- filed_at: 2025-08-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1840229/000117184325005405/0001171843-25-005405-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1840229/000117184325005405/f8k_081425.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-25-005405
- JSON: https://secwatch.observer/filing/0001171843-25-005405.json
- Plain text: https://secwatch.observer/filing/0001171843-25-005405.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.